Regarding the therapeutic approach, these relevant mutations may be used for drug selection: for PALB2 mutations, a response of the tumours has been registered for PARP inhibitors [37,38], mitomycin C [39] and platinum compounds [40]. This evidence concerns the gene PARP1 and neoplasm.